Skip to main content
Caplight Logo









Genespire

Genespire

Private
MilanHealthcare & Life Scienceshttps://genespire.com/en/homepage/

Last Round

Series B

Sep 25, 2024

Total Funding Raised

$69.39M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Genespire is a biotechnology company that develops off-the-shelf gene therapies for pediatric patients affected by genetic diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials

Business Model

B2B

Customer Profile

Government Contracts, Services & Consulting

AI Layer

Non-AI

Keywords

gene therapyoff-the-shelf gene therapycell and gene therapyCGTlentiviral vectorimmune shielded vectorrare genetic diseasesISLV platforminherited metabolic diseasesprimary immune deficienciesmethylmalonic acidemiaMMAorphan diseasesone-time treatmentclinical stage biotechex vivo gene editingHSC therapy

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Genespire Comparables

Compare Genespire with similar companies based on industry and business-model similarity.

Genespire comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
iECURE
81%
Eli Lilly and Company
78%
Vivet Therapeutics
77%

Genespire Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BSep 25, 2024
Series AApr 29, 2020

Genespire Investors

Notable investors and investment history

Genespire investors
InvestorRounds
XGEN VentureSeries B
Indaco Venture Partners SGRSeries B
CDP Venture Capital SGRSeries B
Sofinnova PartnersSeries A, Series B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 28, 2026

    Monthly visitors grew 286% MoM, from 317 to 1.2K.

  • Apr 4, 2026

    Monthly visitors increased 54% MoM.

Genespire Filings

Explore SEC and related filing metadata, where available.

Genespire filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Genespire's valuation, stock price, and market status.

Is Genespire a public or private company?

Genespire is a private company.

What is the current stock price of Genespire?

Genespire is a private company with no public stock price. No recent secondary market data is available.

How much is Genespire worth (valuation)?

Valuation information for Genespire is not publicly available.

Can I buy Genespire stock?

Genespire shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Genespire's last funding round?

Genespire's most recent funding round was Series B on September 25, 2024.

Who are the main investors in Genespire?

Key investors in Genespire include XGEN Venture, CDP Venture Capital SGR, Sofinnova Partners.

Will Genespire IPO soon?

No public IPO plans have been announced for Genespire.

How can I track Genespire secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Genespire's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersMilan
Employee Range12
Year Founded2020
Last FundingSep 25, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?